- Home
- GIX vs VNDA Comparison
GIX vs VNDA Comparison
Compare GIX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GIX | VNDA |
|---|---|---|
| Founded | 2025 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.4M | 361.4M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GIX | VNDA |
|---|---|---|
| Price | $9.99 | $5.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 90.3K | ★ 907.6K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.80 | $4.27 |
| 52 Week High | $9.99 | $9.91 |
Technical Indicators
Market Signals| Indicator | GIX | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 74.64 | 48.33 |
| Support Level | $9.92 | $4.94 |
| Resistance Level | N/A | $5.50 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 100.00 | 38.24 |
Price Performance
Historical ComparisonAbout GIX GigCapital9 Corp. Class A Ordinary Share
GigCapital9 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.